Inflammation is a novel target for therapeutic interventions in myeloid neoplasms. Specific subsets of LR-MDS may benefit and others may probably not. More work needed to better understand. Thanks to Marie Schneider, Clara Rolfs, Michael Cross and the entire MDS team!
For article: Click here